Unfinished business: An assessment of the national approach to improving cancer services in England 1995–2015 – The Health Foundation

HEalth Foundation assessment of strategic approach to cancer care in the NHS in England: This report looks at progress in cancer care over two decades. It finds that progress has been made on reducing mortality, and improving the chances of

Screening Quality Assurance visit report: NHS Cervical Screening Programme Barking, Havering and Redbridge University Hospitals NHS Trust – Public Health England

The findings in this report relate to the quality assurance (QA) visit of the Barking, Havering and Redbridge University Hospitals NHS Trust screening service on 10 and 16 May 2018.

Screening Quality Assurance visit report: NHS Breast Screening Programme North and Mid Hampshire – Public Health England

The findings in this report relate to the quality assurance visit of the North and Mid Hampshire screening service held on 9 May 2018.

Screening Quality Assurance visit report: NHS Breast Screening Programme Bolton Breast Screening Service – Public Health England

The findings in this report relate to the quality assurance visit of the Bolton breast screening service held on 14 March 2018.

Screening Quality Assurance visit report: NHS Breast Screening Programme Dudley, Wolverhampton and South West Staffordshire – Public Health England

The findings in this report relate to the quality assurance visit of the Dudley, Wolverhampton and South West Staffordshire screening service held on 29 January 2018.

Screening Quality Assurance visit report: NHS Breast Screening Programme North Derbyshire and Chesterfield – Public Health England

The findings in this report relate to the quality assurance (QA) visit to the North Derbyshire and Chesterfield breast screening service held on 21 June 2017.  

Screening Quality Assurance visit report: NHS Breast Screening Programme Hull and East Yorkshire Hospitals NHS Trust – Public Health England

The findings in this report relate to the quality assurance (QA) visit to the Humberside Breast Screening Programme (BSP) held on 10 November 2016.

Screening Quality Assurance visit report: NHS Cervical Screening Programme Leeds Teaching Hospitals NHS Trust – Public Health England

The findings in this report relate to the quality assurance visit of the Leeds Teaching Hospitals NHS Trust screening service held on 9 and 10 May 2018.

A data-driven approach to personalised cancer care – REFORM

It is no surprise that improving cancer care is a priority for the Government. A key announcement in the Prime Minister’s 2018 Conservative Party Conference speech was the launch of a new cancer strategy to improve survival rates through faster

Cabozantinib for untreated advanced renal cell carcinoma: Technology appraisal guidance [TA542] – NICE

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal

It only takes a minute girl: women’s perceptions of cervical screening in Blackpool: full report – Liverpool John Moores University Centre for Public Health

This report is stage one of a larger project to increase coverage of cervical cancer screening in Blackpool. About 22 percent of young women aged 25 to 29 years (994 women) and 10 percent of women aged 30 to 34 years

Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer: Interventional procedures guidance [IPG628] – NICE

Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder. This guidance replaces NICE interventional procedures guidance on intravesical microwave

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia: Technology appraisal guidance [TA541] – NICE

Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma: Technology appraisal guidance [TA540]

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults. Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours: Technology appraisal guidance [TA539] – NICE

Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults. Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive

AlignRT in breast cancer radiotherapy: Medtech innovation briefing [MIB157] – NICE

The technology described in this briefing is the AlignRT patient position monitoring system. This briefing focuses on its use during breast cancer radiation therapy. The innovative aspect is that it may avoid inaccurate treatment by precisely tracking a patient’s position

Dinutuximab beta for treating neuroblastoma: Technology appraisal guidance [TA538] – NICE

Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over. Recommendations Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least